Literature DB >> 34313711

Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis.

Guillaume Fond1,2, Katlyn Nemani3, Damien Etchecopar-Etchart1, Anderson Loundou1, Donald C Goff3, Seung Won Lee4, Christophe Lancon1,2, Pascal Auquier1, Karine Baumstarck1, Pierre-Michel Llorca2,5, Dong Keon Yon6, Laurent Boyer1,2.   

Abstract

Importance: Heterogeneous evidence exists for the association between COVID-19 and the clinical outcomes of patients with mental health disorders. It remains unknown whether patients with COVID-19 and mental health disorders are at increased risk of mortality and should thus be targeted as a high-risk population for severe forms of COVID-19. Objective: To determine whether patients with mental health disorders were at increased risk of COVID-19 mortality compared with patients without mental health disorders. Data Sources: For this systematic review and meta-analysis, MEDLINE, Web of Science, and Google Scholar were searched from inception to February 12, 2021. Bibliographies were also searched, and the corresponding authors were directly contacted. The search paradigm was based on the following combination: (mental, major[MeSH terms]) AND (COVID-19 mortality[MeSH terms]). To ensure exhaustivity, the term mental was replaced by psychiatric, schizophrenia, psychotic, bipolar disorder, mood disorders, major depressive disorder, anxiety disorder, personality disorder, eating disorder, alcohol abuse, alcohol misuse, substance abuse, and substance misuse. Study Selection: Eligible studies were population-based cohort studies of all patients with identified COVID-19 exploring the association between mental health disorders and mortality. Data Extraction and Synthesis: Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was used for abstracting data and assessing data quality and validity. This systematic review is registered with PROSPERO. Main Outcomes and Measures: Pooled crude and adjusted odds ratios (ORs) for the association of mental health disorders with mortality were calculated using a 3-level random-effects (study/country) approach with a hierarchical structure to assess effect size dependency.
Results: In total, 16 population-based cohort studies (data from medico-administrative health or electronic/medical records databases) across 7 countries (1 from Denmark, 2 from France, 1 from Israel, 3 from South Korea, 1 from Spain, 1 from the UK, and 7 from the US) and 19 086 patients with mental health disorders were included. The studies covered December 2019 to July 2020, were of good quality, and no publication bias was identified. COVID-19 mortality was associated with an increased risk among patients with mental health disorders compared with patients without mental health disorders according to both pooled crude OR (1.75 [95% CI, 1.40-2.20]; P < .05) and adjusted OR (1.38 [95% CI, 1.15-1.65]; P < .05). The patients with severe mental health disorders had the highest ORs for risk of mortality (crude OR: 2.26 [95% CI, 1.18-4.31]; adjusted OR: 1.67 [95% CI, 1.02-2.73]). Conclusions and Relevance: In this systematic review and meta-analysis of 16 observational studies in 7 countries, mental health disorders were associated with increased COVID-19-related mortality. Thus, patients with mental health disorders should have been targeted as a high-risk population for severe forms of COVID-19, requiring enhanced preventive and disease management strategies. Future studies should more accurately evaluate the risk for patients with each mental health disorder. However, the highest risk seemed to be found in studies including individuals with schizophrenia and/or bipolar disorders.

Entities:  

Mesh:

Year:  2021        PMID: 34313711      PMCID: PMC8317055          DOI: 10.1001/jamapsychiatry.2021.2274

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   25.911


  43 in total

1.  COVID-19 Era Recessional Mortality Continues the Impact of Prepandemic Recessions on Mortality.

Authors:  Nga Tq Nguyen; Hoa Q Nguyen; Ciaran O'Neill
Journal:  Am J Public Health       Date:  2021-10-28       Impact factor: 9.308

2.  Fluoxetine and Molnupiravir: A Synergistic Combination for COVID-19 Treatment?

Authors:  Yaser Pashaei
Journal:  Hosp Pharm       Date:  2022-01-31

3.  Prevalence of and Factors Associated With Post-Coronavirus Disease 2019 (COVID-19) Condition in the 12 Months After the Diagnosis of COVID-19 in Adults Followed in General Practices in Germany.

Authors:  Karel Kostev; Lee Smith; Ai Koyanagi; Louis Jacob
Journal:  Open Forum Infect Dis       Date:  2022-07-04       Impact factor: 4.423

4.  Mental Health Conditions and Severe COVID-19 Outcomes after Hospitalization, United States.

Authors:  Alain K Koyama; Emilia H Koumans; Kanta Sircar; Amy M Lavery; Jean Y Ko; Joy Hsu; Kayla N Anderson; David A Siegel
Journal:  Emerg Infect Dis       Date:  2022-07       Impact factor: 16.126

Review 5.  Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity.

Authors:  Bart N Ford; Jonathan Savitz
Journal:  Immun Ageing       Date:  2022-07-14       Impact factor: 9.701

6.  How Different Pre-existing Mental Disorders and Their Co-occurrence Affects COVID-19 Clinical Outcomes? A Real-World Data Study in the Southern United States.

Authors:  Shan Qiao; Jiajia Zhang; Shujie Chen; Bankole Olatosi; Suzanne Hardeman; Meera Narasimhan; Larisa Bruner; Abdoulaye Diedhiou; Cheryl Scott; Ali Mansaray; Sharon Weissman; Xiaoming Li
Journal:  Front Public Health       Date:  2022-06-16

7.  COVID-19 Booster Vaccination Among Individuals With Schizophrenia in Israel.

Authors:  Dana Tzur Bitan; Khalaf Kridin; Noga Givon-Lavi; Israel Krieger; Ehud Kaliner; Arnon Dov Cohen; Orly Weinstein
Journal:  JAMA Psychiatry       Date:  2022-05-01       Impact factor: 25.911

8.  Mental & addictive disorders - Even more important during & after the COVID-19 pandemic.

Authors:  Jürgen Rehm
Journal:  Indian J Med Res       Date:  2021-04       Impact factor: 5.274

9.  The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach.

Authors:  Christoph U Correll; Craig Chepke; Paul Gionfriddo; Joe Parks; Phyllis Foxworth; Anirban Basu; Teri S Brister; Dawn Brown; Christopher Clarke; Youssef Hassoun
Journal:  BMC Psychiatry       Date:  2022-01-10       Impact factor: 3.630

10.  COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review.

Authors:  Marc De Hert; Victor Mazereel; Marc Stroobants; Livia De Picker; Kristof Van Assche; Johan Detraux
Journal:  Front Psychiatry       Date:  2022-01-13       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.